Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q3 2020 · 10-Q
Revenue$152.93M$152.93M−1.7% vs Q3 2019 Net Income-$11.52M-$11.52MN/M vs Q3 2019 EPS Diluted-$0.39-$0.39N/M vs Q3 2019 Gross Profit$20,047,000−7.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flowderived$10,584,000−16.3% Free Cash Flowderived$4,495,000N/M Margins · derivedGross margin13.1%−0.8 pt vs Q3 2019
Operating margin-9.8%−11.9 pt vs Q3 2019
Net margin-7.5%−8.2 pt vs Q3 2019
ended Feb 23, 2020 · filed Apr 3, 2020 · 40 d after period end